About PACT

spacerNational Heart, Lung, and Blood Institutespacer
spacerSteering CommitteeExternal Expert Panelspacer
5 Cell Processing FacilitiesCoordinating Center The Emmes Corporationspacer
Center for Cell and Gene Therapy, Baylor College
of MedicineCenter for Biomedicine and Genetics, 
City of HopeInterdisciplinary Stem 
Cell Institute, Miller 
School of Medicine, 
University of MiamiUniversity of Minnesota Molecular and Cellular TherapeuticsMoffitt Cancer and Research Institute

 

The National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health (NIH), is supporting the initiative for a Coordinating Center and five facilities for the production and testing of novel cell therapies.

The PACT Cell processing facilities:

  • Center for Cell and Gene Therapy, Baylor College of Medicine (HHSN268201600015I) – PI: Adrian Gee, MI Biol
  • Center for Biomedicine and Genetics, City of Hope (HHSN268201600011I) – PI: Joseph Gold, PhD
  • Interdisciplinary Stem Cell Institute Cellular Manufacturing Program (ISCI-CMP), University of Miami, Miller School of Medicine (HHSN268201600012I) – PI: Joshua Hare, MD
  • University of Minnesota, Molecular and Cellular Therapeutics (HHSN268201600014I) – PI: David H. McKenna, Jr., MD
  • Moffitt Cancer Center (HHSN268201600013I) – PI: Linda Kelley, PhD
  • PACT Coordinating Center (HHSN268201600020C) – The Emmes Corporation – PI: Robert Lindblad, MD

The second competitive renewal of the PACT program will continue to provide the services that were identified as essential for the advancement of cellular therapy research by the previous PACT External Advisory Panel, investigators using PACT services, NIH working groups, and NHLBI staff. These services include providing support for IND-enabling translational research, and diversifying the cell therapy expertise within the program. The Cell Processing Facilities are committed to providing the investigator the data needed to support an Investigational New Drug (IND) application. The PACT Coordinating Center serves as the monitor and coordinator for organizational and regulatory aspects of the program.  The Cell Processing Facilities were selected to meet the needs of the program by diversifying the cell therapy expertise and permits the capability to manufacture and ship cell therapy products that are not feasible over lengthy distances between the facility and the requesting investigator.